# Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

> **NCT00290771** · PHASE2 · TERMINATED · sponsor: **Novartis** · enrollment: 231 (actual)

## Conditions studied

- Recurrent Glioblastoma Multiforme (GBM)

## Interventions

- **DRUG:** Imatinib tablets
- **DRUG:** Hydroxyurea capsules

## Key facts

- **NCT ID:** NCT00290771
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 231 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2011-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290771, "Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00290771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*